Analyst Price Targets — CRVS
Latest News for CRVS
Shares of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS - Get Free Report) were up 5.1% during mid-day trading on Friday. The company traded as high as $14.91 and last traded at $14.9910. 120,438 shares traded hands during mid-day trading, a decline of 95% from the average session volume of 2,365,483 shares. The stock had previously closed
David Scott Moore acquired 21,700 common shares for a transaction value of approximately $250,000 on June 11, 2026. This transaction marks Moore's first investment in the business.
SOUTH SAN FRANCISCO, Calif. , June 09, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has participated in a new $13. 5 million financing for Angel Pharmaceuticals Ltd. (Angel Pharma), the Company's collaboration partner in China.
$13.5 million financing, including $5 million from Corvus, supports ongoing generation of soquelitinib clinical data in China for atopic dermatitis and asthma, which are indications also in development by Corvus in the United States $13.5 million financing, including $5 million from Corvus, supports ongoing generation of soquelitinib clinical data in China for atopic dermatitis and asthma, which are indications also…
Corvus Pharmaceuticals, Inc. (CRVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CRVS.
U.S. House Trading
No House trades found for CRVS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.